Recently added to the BioPortfolio report store,
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015 is a new report from
Global Markets Direct published on 2015-07-30.
This 68-page report
is available in PDF
from $2000.
Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015’, provides an overview of the Onychomycosis (Tinea Unguium)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
…
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Onychomycosis (Tinea Unguium) Overview 8
Therapeutics Development 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9
Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10
Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11
Onychomycosis (Tinea Unguium) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Onychomycosis (Tinea Unguium) - Products under Development by Companies 15
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 16
Anacor Pharmaceuticals, Inc. 16
Eisai Co., Ltd. 17
Helix BioMedix, Inc. 18
Hexima Limited 19
Meiji Seika Pharma Co., Ltd. 20
Moberg Pharma AB 21
NAL Pharmaceuticals Ltd. 22
Nihon Nohyaku Co., Ltd. 23
Novabiotics Limited 24
Nuvo Research Inc. 25
Viamet Pharmaceuticals, Inc. 26
Onychomycosis (Tinea Unguium) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AN-2718 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
E-1224 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ELS-160 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HB-1275 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
HXP-124 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
luliconazole - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ME-1111 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
NAL-3216 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NP-213 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
terbinafine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
terbinafine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VT-1161 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 53
Onychomycosis (Tinea Unguium) - Dormant Projects 58
Onychomycosis (Tinea Unguium) - Discontinued Products 61
Onychomycosis (Tinea Unguium) - Product Development Milestones 62
Featured News & Press Releases 62
Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical…
For more information open Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015.
SKU: GMDHC6868IDB
